DBC-664 in Adult Patients With Solid Tumors

Summary

DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Malignant Germ Cell Tumor
• Lung Adenocarcinoma
• Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma
• Urothelial Carcinoma
• Endometrial Adenocarcinoma
• Ovarian Adenocarcinoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Duboce Biopharmaceuticals, Inc.

Last updated on ClinicalTrials.gov

September 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites